Cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction: recent advances, controversies, and future directions

Heerajnarain Bulluck MBBS, PhD1,2, Rohan Dharmakumar PhD3,4, Andrew E. Arai MD5, Colin Berry MBCHB, PhD6, Derek J. Hausenloy MD, PhD1,7,8,9,10,11

1The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, UK
2Papworth Hospital NHS Trust, Cambridge, UK
3Biomedical Imaging Research Institute and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
4Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA
5Laboratory for Advanced Cardiovascular Imaging, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
6BHF Glasgow Cardiovascular Research Center, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK
7The National Institute of Health Research University College London Hospitals Biomedical Research Centre, UK
8Barts Heart Centre, St Bartholomew’s Hospital, London, UK
9National Heart Research Institute Singapore, National Heart Centre Singapore
10Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore
11Yong Loo Lin School of Medicine, National University Singapore, Singapore

Running title: The role of CMR in STEMI

Corresponding author:

Professor Derek J Hausenloy
Cardiovascular & Metabolic Diseases Program
Duke-NUS Graduate Medical School Singapore
8 College Road,
Singapore 169857
Tel +65 6516 6719
Email: derek.hausenloy@duke-nus.edu.sg
Abstract

While mortality following ST-segment elevation myocardial infarction (STEMI) is on the decline, the number of patients developing heart failure due to prior myocardial infarction (MI) is on the rise. Apart from timely reperfusion by primary percutaneous coronary intervention (PPCI), there is currently no established therapy for reducing MI size. As such new cardioprotective therapies are required to improve clinical outcomes following STEMI. Cardiovascular magnetic resonance (CMR) has emerged as an important imaging modality for assessing the efficacy of novel therapies for reducing MI size and preventing subsequent adverse left ventricular remodeling. The recent availability of multi-parametric mapping CMR has provided new insights into the pathophysiology underlying myocardial edema, microvascular obstruction, intramyocardial hemorrhage, and changes in the remote myocardial interstitial space following STEMI. In this article, we provide an overview of the recent advances in CMR imaging in reperfused STEMI patients, discuss the controversies surrounding its use, and explore future applications of CMR in this setting.

Keywords: Cardiovascular magnetic resonance; ST-segment elevation myocardial infarction; primary percutaneous coronary intervention; myocardial infarct size; area-at-risk; microvascular obstruction; intramyocardial hemorrhage; T1-mapping; T2-mapping; T2*-mapping; extracellular volume fraction mapping; late gadolinium enhancement
Introduction

Improvements in the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI) have led to a decline in mortality over the past 4 decades\(^1\), with 1-year cardiac mortality in STEMI patients plateauing at around 8%\(^2\). However, morbidity due to post-myocardial infarction (MI) heart failure remains significant, and is on the rise\(^3\). The process of reperfusion itself can paradoxically induce further myocardial injury and cardiomyocyte death, a phenomenon termed ‘myocardial reperfusion injury’.\(^4\) There is currently no effective therapy for reducing myocardial reperfusion injury, despite a wealth of research in this field. This has been partly attributed to undertaking clinical studies despite the lack of reproducible and robust preclinical data and the design of the clinical cardioprotection studies in terms of patient selection and inappropriate timing and mode of delivery of the cardioprotective agent\(^5\). As such, the search continues for a novel and effective therapy for reducing MI size and preventing heart failure, which can be administered as an adjunct to PPCI following STEMI. Cardiovascular magnetic resonance (CMR) has emerged as an important imaging modality for assessing the cardioprotective efficacy of novel therapies for reducing MI size and prevent adverse left ventricle (LV) remodeling in reperfused STEMI patients\(^6,7\). It is currently the gold standard imaging modality for quantifying MI size\(^8\), and is able to detect small subendocardial MI (as little as 1 gram)\(^9\) with good accuracy\(^10\).

With the recent availability of native T1, T2, T2\(^*\) and post-contrast T1-mapping (to derive extracellular volume fraction [ECV] mapping)\(^11\), more in-
depth insights can be obtained into the pathophysiological processes such as the evolution of myocardial edema in the first week post-STEMI\textsuperscript{12, 13}, the chronic manifestation of intramyocardial hemorrhage, and its prognostic significance over microvascular obstruction\textsuperscript{14, 15} and changes in the remote myocardial interstitial space in those developing adverse LV remodeling\textsuperscript{16, 17} following STEMI. In this article, we provide an overview of some of the recent advances in CMR imaging in reperfused STEMI patients, discuss the recent controversies surrounding its use, and explore future applications of CMR in this setting.

**Basic concepts**

In this section, we provide a brief description of some of the basic concepts concerning the use of CMR in STEMI. Table 1 provides an explanation of the more technical terms used throughout this article. Figure 1a also provides an illustration of the various components of the myocardium that can be interrogated by CMR.

*Myocardial Infarct Size*

MI size refers to the infarcted myocardium and is conventionally quantified by late gadolinium enhancement (Table 1 and Figure 1b).\textsuperscript{18} The gadolinium chelate cannot cross the intact cell membranes.\textsuperscript{18} Following acute myocardial necrosis, the cell membranes are ruptured allowing the contrast agent to enter these cells. In the chronic setting, there is also expansion of the
extracellular space due to the collagen deposits and the relatively low residual amount of intact cardiomyocytes in the region of the infarct. Therefore, following gadolinium chelate administration, the contrast redistributes itself from the vascular compartment to the interstitial space and at pseudo-equilibrium a higher concentration of contrast is distributed in areas of acute or chronic MI than in normal myocardium. 19 (Table 1).

*Microvascular Obstruction and Intramyocardial Hemorrhage*

Microvascular obstruction refers to the inability to reperfuse the coronary microcirculation in a previously ischemic region, despite opening the epicardial vessel. 20 Microvascular obstruction can be identified as a dark hypo-intense core within the areas of hyper-enhancement on either early gadolinium enhancement (referred to as early microvascular obstruction) or conventional late gadolinium enhancement sequences (referred to as late microvascular obstruction) - defined in Table 1 and illustrated in Figure 1b.

If the coronary microvasculature injury following STEMI is especially severe, and the integrity of the vessels are damaged, the extravasation of red blood cells into the myocardium can occur - termed intramyocardial hemorrhage. 14 The breakdown products of hemoglobin within the myocardium can be detected as a hypo-intense core 21 within the MI zone on T2*-imaging or T2*-mapping (Figures 1 and 2). Of the two approaches, T2*-mapping has been shown to have greater sensitivity for detecting intramyocardial hemorrhage following STEMI when compared to T2-mapping (Table 1). 22 23
A small study previously showed that the hypointense core on the T1 or T2 maps could provide an alternative method to detect intramyocardial hemorrhage in cases where T2* is not available or not interpretable (Figures 1 and 2)\(^21\) and further studies are needed to confirm these findings.

**Area-at-risk**

The area-at-risk refers to the territory supplied by the infarct-related artery that would have infarcted following STEMI, if reperfusion had not taken place to salvage viable myocardium. The area-at-risk includes both the reversibility injured myocardium (also referred to as the salvaged myocardium) and the infarcted myocardium. Figure 3 shows an example of the edema-based area-at-risk by T1 and T2-mapping and the corresponding MI size on late gadolinium enhancement in a patient presenting with an acute inferior STEMI treated by PPCI.

A number of CMR approaches to delineating the area-at-risk following STEMI have been described (see Table 1). However, they all have their limitations,\(^24\) and although each technique has been validated against histology in the preclinical setting\(^25\)–\(^29\), there is currently no consensus on which CMR method should be used to quantify the area-at-risk in the clinical setting. So far, no studies have compared these techniques, head-to-head, in the same patient cohort. Once the area-at-risk and MI size are known, the myocardial salvage index can be calculated as described in Table 1.
The myocardial salvage index is considered a more sensitive measure for assessing the efficacy of novel cardioprotective therapies, when compared to MI size alone\textsuperscript{30}, as it normalizes the MI size reduction to the area-at-risk, the latter of which varies from patients to patient. As such, the myocardial salvage index may help to reduce sample size for clinical cardioprotection studies in comparison to using MI size alone.\textsuperscript{31}

**Recent advances in the role of CMR in reperfused STEMI patients**

In this section, first of all, we will summarize the advances in the use of T1 mapping to assess MI size. We will then elaborate how CMR has improved our understanding of the relationship between microvascular obstruction and intramyocardial hemorrhage; and the role of MI size, intramyocardial hemorrhage, residual myocardial iron and the remote myocardium in the development of adverse LV remodeling. Finally, we will explore the prognostic significance of these CMR-derived indices in the reperfused STEMI patients.

**T1-mapping for the quantification of MI size**

Post-contrast T1-mapping has recently emerged as a promising technique for the quantification of MI size, as an alternative to conventional late gadolinium enhancement imaging. Bulluck et al\textsuperscript{32} recently showed that post-contrast T1-mapping can accurately quantify acute MI size in a small group of STEMI patients, obviating the need to perform late gadolinium enhancement imaging. Recent studies have also investigated whether native
T1-mapping (pre-contrast) can assess MI size. Kali et al\textsuperscript{33} showed that chronic MI (median of 13.6 years post-MI) could be detected using native T1-mapping at 3T in a small cohort of 25 patients. Liu et al\textsuperscript{34} showed that native T1-mapping at 3T could also identify acute MI size. However, only 58 short-axis T1 maps without microvascular obstruction were analyzed in that study.\textsuperscript{34} These findings are of great interest as one could potentially perform a comprehensive CMR study in STEMI without the need of contrast agent and this approach would also significantly shorten the scan time and make CMR available to a wider range of patients.

Whether ECV on an acute CMR scan can estimate final MI size following STEMI has recently been investigated. Garg et al\textsuperscript{35} showed that an ECV value of 0.46 or above could predict chronic MI size from the acute ECV maps. However, Bland-Altman analysis showed a bias of 1.9\% and wide limits of agreement of ±10.5\% and further studies are therefore needed to build on these findings.\textsuperscript{36} However, as it stands, ECV-mapping may complement late gadolinium enhancement imaging to assess MI size and predict wall motion recovery at follow-up, as recently shown by 2 small studies.\textsuperscript{16, 37}

Despite the promises of T1-mapping in STEMI for measuring MI size, the published studies have been small, and from single-centers. Larger studies are therefore required to confirm these findings, using different field strengths, mapping sequences, and vendors, before they can be more widely adopted.
Relationship between microvascular obstruction and intramyocardial hemorrhage

Serial CMR imaging of STEMI patients in the first few days following PPCI has provided evidence that the incidence and extent of microvascular obstruction and intramyocardial hemorrhage vary with time. The extent of late microvascular obstruction has been reported to peak at 4-12 hours, to remain stable the first 2 days and to reduce in size by day 10 following STEMI.\textsuperscript{14} Furthermore, in those patients with microvascular obstruction persisting at one week, Orn et al\textsuperscript{38} showed that they were more likely to develop adverse LV remodeling compared to those with microvascular obstruction at day 2 only. On the other hand, the detection of intramyocardial hemorrhage has been shown to peak at day 3, and to reduce in incidence by day 10 following PPCI.\textsuperscript{12}

Hamirani et al\textsuperscript{22} showed that intramyocardial hemorrhage (detected by either T2-weighted imaging or T2* imaging) was more strongly associated with late microvascular obstruction (R=0.89 to 0.93) than with early microvascular obstruction (R=0.30). Using the more robust method of T2*-mapping for the detection of intramyocardial hemorrhage, Carrick et al\textsuperscript{14} in 286 patients showed that all patients with intramyocardial hemorrhage also had late microvascular obstruction.

Based on these recent studies\textsuperscript{14, 22, 39, 40}, it appears that early microvascular obstruction occurs in around 60-65%; late microvascular obstruction in around 50-55%; and intramyocardial hemorrhage in around 35-
40% of reperfused STEMI patients. However, the detection of microvascular obstruction and intramyocardial hemorrhage is dependent on the CMR techniques, the timing of imaging, and the definitions used.

**Acute MI size and subsequent adverse LV remodeling**

Conventional theory assumes that the larger the MI size, the higher the LV wall stress, and the LV therefore dilates to maintain the stroke volume as a compensatory mechanism (via the Frank-Starling principle). However, LV dilation, as described by the Laplace relationship, leads to further wall stress and begets more LV dilation, in the absence of compensatory LV hypertrophy. Westman et al\(^4\) have recently proposed that there is an imperfect association between MI size and adverse LV remodeling. They showed in 122 STEMI patients, that 15% of those with MI size <18.5% developed adverse LV remodeling, and 40% of those with MI size ≥18.5% developed adverse LV remodeling. However, Westman et al\(^4\) used a definition of >10ml/m\(^2\) increase in indexed LV end-diastolic volume in their study. A more appropriate definition for adverse LV remodeling post-STEMI by CMR may be a cut-off value of 12% change in LV end-diastolic volume.\(^4\) This study also showed an imperfect association between acute MI size and adverse LV remodeling, and between the presence of microvascular obstruction and adverse LV remodeling.\(^4\) Some patients with large MI size and microvascular obstruction developed reverse LV remodeling and whereas other patients with small MI size and no microvascular obstruction also developed adverse LV
remodeling.\textsuperscript{42} As eluded to by Westman et al\textsuperscript{41}, the development of adverse LV remodeling is complex and multi-factorial and an excessive inflammatory response together with MI size may play an important role following STEMI.

\textit{Residual myocardial iron and adverse LV remodeling}

There are emerging data that intramyocardial hemorrhage at the time of PPCI leads to residual myocardial iron during the convalescent phase, and it may be a source of prolonged inflammation and impact on adverse LV remodeling.\textsuperscript{43} Kali et al\textsuperscript{43} showed in a small cohort of 15 STEMI patients and in 20 canines (with histological validation) that intramyocardial hemorrhage resulted in residual myocardial iron within the MI zone, and this provided a source of prolonged inflammatory burden in the chronic phase. These findings were recently confirmed in a canine model of MI, and the extent of residual iron was strongly correlated with markers of inflammation and adverse LV remodeling.\textsuperscript{44} Roghi et al\textsuperscript{45} found higher levels of non-transferrin bound iron in 7 out of 15 STEMI patients with microvascular obstruction and postulated that intramyocardial hemorrhage could be a source of cardiotoxicity in these patients.

In a small cohort of STEMI patients, Bulluck et al\textsuperscript{15} recently found that intramyocardial hemorrhage and subsequent residual myocardial iron at follow-up were associated with persistently elevated T2 values in the surrounding infarct tissue and with adverse LV remodeling.\textsuperscript{15} Carberry et al\textsuperscript{46} have recently confirmed these findings in a cohort of 203 STEMI patients.
They showed that 36% of their cohort had intramyocardial hemorrhage by T2*-mapping and 59% of those had residual myocardial iron at 6 months. Residual myocardial iron was associated with adverse LV remodeling at 6 months and worse clinical outcomes after a median follow-up of 4 years.\textsuperscript{46} Figure 4a shows an example of a patient with an acute inferior STEMI treated by PPCI, and with late microvascular obstruction and intramyocardial hemorrhage despite restoring normal flow in the epicardial coronary artery during PPCI. At follow-up, there was residual myocardial iron and persistently elevated T2 values in the areas surrounding the residual iron, which may represent persistent myocardial inflammation.

The role of the remote myocardium and clinical outcomes

Whether changes in the extracellular matrix in the remote myocardium (Table 1) in STEMI patients treated by PPCI are associated with adverse LV remodeling, has been a topic of on-going research.\textsuperscript{16, 17, 47-49} Using automated ECV maps, Bulluck et al have showed in a small cohort of 40 STEMI patients that ECV in the remote myocardium was acutely elevated, and this elevation in ECV persisted in those who developed adverse LV remodeling at 5 months, suggesting that remote compensatory changes in the extracellular matrix occurred in this subset of patients.\textsuperscript{16} The increase in acute ECV could have been due to an increase in the intravascular compartment as a compensatory mechanism. At follow-up, the increase in ECV likely represented diffused interstitial fibrosis, as part of the remodeling process. Garg et al\textsuperscript{49} recently
confirmed these findings in a cohort of 50 STEMI patients. Furthermore, they also showed that remote segments with ECV expansion were associated with impaired wall thickening. In a larger cohort of patients (n=131), Carberry et al\textsuperscript{17} showed that the change in ECV of the remote myocardium was a multivariable associate of the change in LV end-diastolic volume at 6 months. Whether this change in ECV could independently predict those at risk of adverse events remains to be tested in future, adequately powered studies. Figure 4b shows an example of the paired acute and follow-up (6 months) late gadolinium enhancement and automated ECV maps with representative regions of interest of the remote myocardium of a patient with an anterior STEMI treated by PPCI.

Carrick et al\textsuperscript{48} demonstrated that higher native T1 of the remote myocardium of 267 reperfused STEMI patients on the acute CMR scan was associated with changes in LV end-diastolic volume from baseline to 6 months, and it was independently associated with adverse cardiac events after a median follow-up of 845 days. Most recently, in a similar number of patients, Reinstadler et al\textsuperscript{47} also showed that the remote native myocardial T1 was independently associated with adverse events, after adjusting for clinical risk factors and other CMR variables after a follow-up of 6 months.

Therefore, T1 mapping has the potential to complement clinical and other CMR-derived parameters to improve the risk-stratification of STEMI patients and warrants further investigation in a multi-center setting.
Acute MI size and clinical outcomes

Morbidity and mortality post-STEMI is closely related to acute MI size. A recent meta-analysis of 2,632 patients showed that MI size measured by CMR or SPECT within a month post-PPCI from 10 randomized controlled trials (RCTs) was strongly associated with 1-year hospitalization for heart failure and all-cause mortality. For every 5% increase in MI size, there was a 20% increase in the relative hazard ratio for 1-year hospitalization for heart failure and all-cause mortality. The event rate was 1.2% in those with MI size ≤ 8% of the LV and there was a stepwise increase to 2.5% in those with MI size >8% - ≤ 17.9% of the LV; 5.6% in those with MI size >17.9% - 29.8% of the LV; and 8.8% in those with MI size >29.8% of the LV. This study adds to the growing body of evidence that acute MI size is prognostic, and therefore remains a valid surrogate endpoint for clinical trials. However, this study also highlights the fact that one of the limitations of using CMR in RCTs is that there is an element of selection bias as only those patients fit enough to tolerate a CMR study would enter these RCTs and the overall event rates were 2.2% and 2.6% for of all-cause mortality and hospitalization for heart failure at 1 year, respectively, much lower than those reported from clinical registries.  

Microvascular obstruction and intramyocardial hemorrhage and clinical outcomes
Both microvascular obstruction and intramyocardial hemorrhage are associated with larger MI size, adverse LV remodeling, and worse clinical outcomes. In a meta-analysis of more than 1000 patients, Van Kranenburg et al showed that the presence of microvascular obstruction was an independent predictor of major adverse clinical outcome at 2 years in STEMI patients, whereas MI size was not independently associated with adverse events. There was a graded reduction in event-free survival in patients with MI size <25% of the LV, with and without microvascular obstruction, and those with MI size >25% of the LV, with and without microvascular obstruction. The prognostic value of microvascular obstruction over MI size for mortality and hospitalization for heart failure was recently confirmed by de Waha et al in a pooled analysis of patient-level data from 7 randomized controlled trials (n=1688) at 1 year and by Symons et al in a longitudinal study of 810 patients following a median follow-up of 5.5 years.

Early studies showed that intramyocardial hemorrhage, detected by T2-weighted images, was closely related to the development of adverse LV remodeling and worse clinical outcomes. Most recently, using T2*-mapping, Carrick et al showed that intramyocardial hemorrhage was more closely associated with adverse clinical outcomes than microvascular obstruction.

Therefore, based on the current evidence discussed so far, the prognosis worsens with larger MI size. Patients with larger MI size are also more likely to have microvascular obstruction and intramyocardial hemorrhage. The prognosis is worse for STEMI patients with microvascular obstruction when
compared to those without microvascular obstruction\textsuperscript{52} and is worst for those with microvascular obstruction and intramyocardial hemorrhage.\textsuperscript{14}

Currently, there are no effective methods to detect those at risk of microvascular obstruction and intramyocardial hemorrhage at the time of PPCI. Amier et al\textsuperscript{53} recently showed that anterior STEMI and use glycoprotein IIb/IIIa inhibitors were associated with the development of intramyocardial hemorrhage. However, this was a retrospective post-hoc analysis and intramyocardial hemorrhage was identified using T2-weighted imaging instead of the more robust T2*-weighted imaging and their findings need to be confirmed in future studies. Furthermore, there are no established therapies to prevent or minimize the burden of microvascular obstruction and intramyocardial hemorrhage in the clinical setting\textsuperscript{4}, although promising results are emerging in the preclinical setting\textsuperscript{54}.

**Current controversies in CMR imaging of STEMI patients**

*Is myocardial edema confined to the infarct zone or does it extend into the salvaged myocardium?*

In the 1980s, Higgins et al\textsuperscript{55} were the first to study myocardial T2 CMR in a canine model of MI. Interestingly, both T2 and T1 were shown to change similarly in the setting of an acute MI. The observed changes were theoretically consistent with myocardial edema, and correlated with the measurements of myocardial water content estimated by wet-weight to dry-weight ratios. The changes in myocardial T2 have been attributed to a
combination of an increase in absolute tissue water, movement of water from the extracellular to the intracellular compartment, and the conversion of protein-bound water to free water.\textsuperscript{56}

Not all experimental and clinical studies have supported the concept that the region of hyper-intensity on T2-weighted images delineates the area-at-risk. Aletras et al\textsuperscript{27} and Tilak et al\textsuperscript{57} validated the edema-based area-at-risk using T2-weighted images against microsphere in reperfused and non-reperfused canine MI. Ubach et al\textsuperscript{58} showed that the area-at-risk derived from T2-weighted imaging matched that obtained from single-photon emission computed tomography, both in animals with and without late gadolinium enhancement.

In contrast, Kim et al\textsuperscript{59} reported that T2-weighted imaging did not depict the area-at-risk in anesthetized dogs that were subjected to different durations of coronary occlusion. MI size by late gadolinium enhancement was compared to the gold standard method of triphenyl tetrazolium chloride staining, and area-at-risk by T2-weighted imaging was compared to the gold-standard method of fluorescent microspheres, 4 days after reperfusion. The T2-weighted hyper-intensity correlated and matched in shape better with the MI size than with the area-at-risk, and these findings were confirmed in a small group of acute MI patients. Although the findings from the canine model of MI may be due to the presence of well-developed collaterals in that species, the T2-weighted sequence in that study was different to what has been used so far by other studies.\textsuperscript{27, 57} In the clinical setting, using hybrid positron emission tomography/CMR imaging in reperfused STEMI patients,
Bulluck et al\textsuperscript{60} recently showed that the area of reduced 18F-fluorodeoxyglucose uptake was significantly larger than the MI size and closely matched the area-at-risk delineated by T2-mapping on the acute scan, supporting the notion that T2-mapping does delineate both the reversibly and the irreversibly injured myocardium within the area-at-risk\textsuperscript{60}. In addition, the areas of reduced 18F-fluorodeoxyglucose uptake within the salvaged myocardium within the area-at-risk were no longer present on a follow-up scan several months later.\textsuperscript{60} Hammer-Hansen et al\textsuperscript{61} have provided further insights on this topic, using a canine model of MI. They showed that T2 values were elevated both in the MI zone and salvaged myocardium, and they were both significantly higher than the T2 values in the remote myocardium.

Therefore, the majority of the current literature supports the notion that edema, assessed by CMR using T2-mapping, occurs both in the irreversibly and reversibly injured myocardium during the first week of a reperfused STEMI in the clinical setting.\textsuperscript{60, 62-64}

\textit{Dynamic changes in the edema-based area-at-risk during the first week in reperfused STEMI patients}

It was initially believed that the extent of myocardial edema was stable in the first week in STEMI patients\textsuperscript{63, 65}, although both these studies only performed T2-weighted imaging on days 1 and 7. Emerging evidence suggests that the extent of myocardial edema is dynamic. Hammer-Hansen et al\textsuperscript{61} have shown in a canine model of reperfused MI, that at 2 hours, T2
values were higher in both the infarcted and salvaged myocardium when compared to those who had the scan at 48 hours, highlighting that the extent of myocardial edema within the first few days of an MI is dynamic.

Fernandez-Jimenez et al. 66 studied the interplay between myocardial water content (using desiccation) and T2 relaxation times in a porcine model of reperfused MI. They reported a ‘bimodal’ pattern of edema, appearing at 2 hours, resolving by 24 hours and then reappearing on day 4 and peaking at day 7. The first wave of edema was attributed to myocardial reperfusion injury, and the second wave of edema was attributed to inflammation during the tissue-healing phase.67 However, they did not take into account the presence of microvascular obstruction and intramyocardial hemorrhage, which may have interfered with their T2 measurements, and they had a small sample size of 5 pigs at each time point. Furthermore, the same animals were not serially scanned. Most recently, Jimenez et al showed that the bimodal edematous response of the infarct related territory was present in humans as well. However, they used the less robust T2-weighted imaging modality instead for both quantifying the extent of the edema-based area-at-risk and for detecting intramyocardial hemorrhage. It was not clear how many of their 14 patients had intramyocardial hemorrhage in that cohort. Furthermore, on a patient-level basis (their supplementary material figures 3 and 4), not all patients displayed a bimodal response for of the intensity and extent of edema in the infarct-related territory.

It was initially believed that edema is stable in the first week of an MI.63, 65 However, both these studies only performed T2-weighted imaging on days
1 and 7 and the peak in the edema-based area-at-risk shown by Carrick et al\textsuperscript{12} on day 3 was therefore not identified by the previous 2 studies.\textsuperscript{63}

In contrast to these studies, in a cohort of 30 patients with serial imaging, Carrick et al\textsuperscript{12} found that the extent of myocardial edema was maximal at day 3, and decreased by day 10 following PPCI, suggesting a unimodal peak in myocardial edema in the first few days following reperfusion. Interestingly, in STEMI patients with intramyocardial hemorrhage, they did observe a bimodal pattern in T2 and T2* values within the MI core, whereas in patients without intramyocardial hemorrhage, only a unimodal pattern in T2 and T2* values was observed, suggesting that the presence of intramyocardial hemorrhage may have been responsible for the apparent bimodal edema pattern in T2 and T2* values.

Nordlund et al\textsuperscript{68} recently provided some evidence that there was no bimodal pattern of edema in the clinical setting. They combined data from 3 studies involving 215 patients and showed there were no difference in size, quality of the T2-weighted images and the ability to detect the culprit territory when patients having a CMR study on Day 1 to Day 6 onwards were compared.

Given the dynamic changes in the extent of edema and acute MI size over the first few days following STEMI, it is important that future clinical cardioprotection studies define the time-window for performing the acute CMR scan in order to optimize the quantification of both acute MI size and AAR.
There is currently no consensus on the optimal timing for performing the acute CMR scan although 3-5 days\textsuperscript{6} and 4-7 days\textsuperscript{13} post-PPCI have been proposed.

*Cardioprotective therapies and the edema-based area-at-risk in reperfused STEMI patients*

The utility of T2-weighted imaging for quantifying the area-at-risk has been put into question because certain cardioprotective therapies have been shown to reduce not only MI size, but the extent of myocardial edema measured by T2-weighted and T2-mapping imaging. Ischemic postconditioning\textsuperscript{69} and remote ischemic conditioning using transient arm or leg ischemia and reperfusion) \textsuperscript{70} have been shown to reduce both MI size and the extent of edema delineated by T2-mapping and T2-weighted imaging, leading to an underestimation of the area-at-risk by these techniques. However, these were small studies of reperfused STEMI patients and they were not adequately powered to assess that endpoint. Intuitively, the fact that a cardioprotective therapy can reduce MI size, it should be expected to also limit the extent of myocardial edema, which itself is the result of myocardial ischemia and reperfusion injury.

However, in a recently published large study of 696 STEMI patients by Eitel et al \textsuperscript{71}, ischemic postconditioning or a combination of remote ischemic conditioning and ischemic postconditioning did not reduce the extent of myocardial edema when compared to the control arm. Furthermore, drugs such as metoprolol\textsuperscript{72} and exenatide\textsuperscript{73} that were effective at increasing the myocardial salvage index did not reduce the extent of myocardial edema. One
potential explanation for this discrepancy could be that those therapies that are potent enough to reduce MI size in reperfused STEMI patients, are capable to reduce the extent of myocardial edema. In contrast, those therapies that are less potent and do not reduce MI size, and only increase myocardial salvage, do not affect the extent of myocardial edema. Either way, these findings may question the use of edema-based area-at-risk measured by CMR to assess myocardial salvage in clinical cardioprotection studies.

The optimal timing of late gadolinium enhancement imaging for acute and chronic MI size quantification

Acute MI size has been shown to be dynamic and to decrease significantly in size between Day 1 and Day 7 post-STEMI. In a recent study by Carrick et al, MI size was shown to be similar between days 1 and 3, and reduced in size by day 10. Jablonowski et al recently provided some mechanistic insights into this phenomenon in a porcine model of acute MI. At day 1, they found higher ECV values in the peri-infarct zone that could be due to severe edema or a mixture of infarcted and salvaged myocardium in that area that contributed to the overestimation of MI size. By 7 days, the ECV values in the peri-infarct zone decreased to the same level as the rest of the salvaged myocardium, such that MI size assessed by late gadolinium enhancement matched that by histology.

Acquiring late gadolinium enhancement too early (<8 minutes post–contrast administration) can result in an overestimation of MI size, and
acquiring late gadolinium enhancement at 25 minutes for acute MI size has been shown to be a better predictor of LV recovery. However waiting 25 minutes post-contrast administration may be difficult to apply in the clinical setting due to time constraints, and would affect workflow. As such, late gadolinium enhancement images are currently acquired 10-15 minutes post-contrast, at the expense of still overestimating MI size to some extent.

Several studies have already shown a significant regression in MI size (by 30-35%) occurring between the acute CMR scan and the chronic phase. There are several factors responsible for this observation. First of all, the composition of the different tissues being identified by late gadolinium enhancement in the acute (myocardial necrosis compounded with edema, intramyocardial hemorrhage and microvascular obstruction) and chronic phase (focal replacement fibrosis) is different. The regression of MI size between the acute, sub-acute and chronic phases therefore represents the gradual resolution of edema, intramyocardial hemorrhage and microvascular obstruction and the gradual replacement of the necrotic cardiomyocytes with focal scars.

As it stands, the optimal timing of CMR for MI size is not well established but late gadolinium enhancement appears to stabilize by 10 days post the index event. In most centers, STEMI patients with an uncomplicated inpatient stay are discharged within the first week. Logistically, this would mean that patients would have to come back for the CMR scan and this may lead to a proportion of patients dropping out. Efforts are underway
to attempt to standardize the acquisition of CMR for clinical cardioprotection studies. 

Future directions

The need to standardize the use of CMR in reperfused STEMI patients

Both acute and chronic MI sizes by CMR have been shown to be stronger predictors of clinical outcomes when compared to LV ejection fraction or LV volumes. Therefore, due to the robustness and high reproducibility of CMR to quantify MI size, both acute and chronic MI size are increasingly being used as surrogate endpoints for randomized control trials assessing the effectiveness of new cardioprotective therapies, and can reduce the sample size required. However, acute MI size is influenced by a number of factors including the timing of the CMR scan, the dose of contrast used, the time elapsed following contrast administration and acquisition of late gadolinium enhancement imaging and the method used for the quantification of MI size. Therefore, there is an urgent need for the CMR community to come up with a consensus position to standardize the acquisition of late gadolinium enhancement imaging and the quantification of MI size in future studies. This would no doubt help to strengthen the robustness of this technique and would also facilitate prospective or retrospective collaborative research with merging of CMR data from different centers around the world.
Towards improving the tolerability and accessibility of CMR in reperfused STEMI patients

There have already been some advances in free-breathing and motion corrected T2\(^8\) and T2*-mapping\(^8\) and late gadolinium enhancement imaging\(^8\) negating the need for breath-holding and helping to accelerate the acquisition of these sequences. Other developments in real-time cine imaging for LV ejection fraction and future refinements in CMR fingerprinting techniques (for robust and fast acquisition of simultaneous T1 and T2-mapping data per slice within one breath-hold) will further reduce scan time, and will be highly desirable in the acute STEMI setting. These developments would make CMR, which is currently confined to those fit enough to lie inside the scanner for at least 30-45 minutes, accessible to a wider number of patients. Furthermore, reducing the duration of the scan to 20-30 minutes could also potentially reduce the cost of a scan, and improve the participation of more centers in STEMI-related CMR research. However, most of these new developments are still in the validation phase and are not available to all CMR vendors and platforms.

The use of gadolinium chelates is not recommended in those with a glomerular filtration rate < 30 mL/min/1.73m\(^2\), to minimize the risk of nephrogenic systemic fibrosis, and constitutes a contraindication in CMR-based clinical cardioprotection studies. Furthermore, the Food and Drug Administration (FDA) has recently issued a new warning regarding gadolinium remaining in patients’ brainstem, for months to years after receiving these drugs. However, gadolinium retention has not been directly linked to adverse
events in patients with normal renal function and the current benefits of using gadolinium chelates outweigh any potential risks. Therefore, the potential for non-contrast CMR imaging such as T1 mapping\textsuperscript{87} and T2\textsuperscript{*} mapping\textsuperscript{14} to provide adequate prognostic information over post-contrast imaging modalities and that could be applied to all patients, irrespective of renal function, warrants further investigation.

**CMR as a tool to risk-stratify and guide management in STEMI patients at risk of developing adverse LV remodeling and subsequent heart failure**

A number of cardioprotective therapies have had promising results in the experimental setting for reducing MI size and preventing adverse LV remodeling, but have failed to be translated into the clinical setting.\textsuperscript{88} A more targeted approach using CMR to identify those most at risk (e.g. according to their acute MI size or according to the presence or absence of microvascular obstruction) may improve the translation of those promising experimental results in the clinical setting, to prevent adverse LV remodeling and reduce the onset of heart failure in these patients. Stiermaier et al\textsuperscript{89} and Pontone et al\textsuperscript{90} most recently proposed CMR risk scores to identify those at high risk of adverse events. Their approach would be ideal to identify high-risk patients but the CMR indices and cut-off values included in each study differed and further validation work is required to build on their findings. Furthermore, CMR could identify those with intramyocardial hemorrhage, and they could be targeted with anti-inflammatory agents or chelation therapy\textsuperscript{15, 91}, to minimize
the cardiotoxic effects of the residual iron (which has been shown to occur in two-third of patients with intramyocardial hemorrhage from a pooled analysis of 4 studies)\textsuperscript{46} during the convalescent phase of an acute STEMI and this warrants further investigation.

\textit{CMR as a tool for risk-stratification of STEMI patients at risk of arrhythmic events}

The current guidelines recommend an implantable cardioverter defibrillator (ICD) for primary prevention in those with symptomatic heart failure and LVEF\textless{}35\% 40 days following the index event.\textsuperscript{92} However, mortality within the first 30 days post-MI has been shown to be the highest \textsuperscript{93} but is predominantly believed to be due to MI or myocardial rupture.\textsuperscript{94} Despite that, a quarter of those deaths are still due to ventricular arrhythmias \textsuperscript{94} and currently there is no established tool to risk stratify these patients in the acute phase of an MI. Acute MI size (cut-off of 23.5g/m\textsuperscript{2} or 31\% of the LV) in combination with LVEF (cut-off of 36\%) by CMR within the first week on an MI has been shown to predict adverse arrhythmic cardiac events at 2 years.\textsuperscript{95} Other studies have shown that CMR in the chronic phase could also be used to predict sudden cardiac death using the peri-infarct zone extent \textsuperscript{96} or chronic MI size \textsuperscript{97} in combination with LVEF. Furthermore, residual myocardial iron as a consequence of intramyocardial hemorrhage has also been shown to be pro-arrhythmic.\textsuperscript{98} Although all these were relatively small and single-center studies, CMR has shown promise to improve the risk-stratification of STEMI
patients at risk of ventricular arrhythmias. With the availability of inline, automated ECV-mapping\(^{99}\) and free-breathing T2*-mapping\(^{85}\), characterization of the infarct size and peri-infarct zone and infarct core may become more objective and CMR would play an invaluable role to identify those most likely to benefit from a primary prevention ICD in a near future.

**Conclusion**

Over the last few years, CMR scans performed in the acute phase of reperfused STEMI have improved our understanding of the changes occurring in the infarcted, salvaged, and remote myocardium, and have provided insights into the impact of MI size, microvascular obstruction and intramyocardial hemorrhage on clinical outcomes. There are ongoing controversies surrounding the use of CMR to delineate the area-at-risk, and the dynamic changes in myocardial edema in the first few days following PPCI. However, more work is ongoing and CMR holds promise to become accessible to more patients, and to be used as a tool to risk-stratify patients, guide treatment, and improve clinical outcomes post-PPCI in the near future.

**Acknowledgements**

This work was supported by the following: British Heart Foundation (FS/10/039/28270); the National Institute for Health Research University College London Hospitals Biomedical Research Centre; Duke-National University Singapore Medical School; the Singapore Ministry of Health’s
National Medical Research Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017) and Collaborative Centre Grant scheme (NMRC/CGAug16C006); the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2016-T2-2-021); and the EU-CARDIOPROTECTION CA16225 Cooperation in Science and Technology (COST) Action; the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health, DHHS; extramural funding from National Heart, Lung, and Blood Institute, National Institutes of Health, DHHS (R01 HL136578 and R01 HL133407); the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177), BHF grants (FS/15/54/31639, PG/11/2/28474, PG/14/64/31043), Medical Research Scotland, and the Chief Scientist Office. Professor Berry was supported by a Senior Fellowship from the Scottish Funding Council.

References


40. de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I, Ben-Yehuda O, Jenkins P, Thiele H and Stone GW. Relationship between microvascular obstruction and adverse events following primary primary


35


106. Dall’Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, Cuculi F, Kharbanda RK, Banning AP, Choudhury RP, Karastinos TD and Neubauer S. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial
Figure 1: (a) Schematic representation of the different components of the myocardium in a patient with reperfused STEMI and; (b) methods for delineating the area-at-risk, MI size, microvascular obstruction and intramyocardial hemorrhage by CMR.

Figure 1a illustrates the various components of the myocardium in a reperfused STEMI patient that can be assessed by CMR, namely the area-at-risk, salvaged myocardium, the area of hyperenhancement and the hypointense core on late gadolinium enhancement images and the remote myocardium. The MI size includes both the areas of hyperenhancement and the hypointense core on late gadolinium enhancement images. The hypointense core on late gadolinium enhancement represents microvascular obstruction and a proportion of patients would also have intramyocardial hemorrhage within these areas (areas of low T2* on T2*-weighted images or mapping). The area-at-risk is a combination of both the MI size and the salvaged myocardium.

Figure 1b illustrates the CMR-based methods and their timing during CMR acquisition for delineating the area-at-risk, MI size, microvascular obstruction (early and late) and intramyocardial hemorrhage. The most robust method for demarcating the area-at-risk currently is T1 and T2-mapping. Late gadolinium enhancement is the gold standard for detecting MI size and late microvascular obstruction. T2*-mapping is currently the gold standard to detect intramyocardial hemorrhage. The table provides an indication of the abilities of each sequence to detect each component of an MI by STEMI and graded as: ✔✔✔: Robust, have been shown by several studies; ✔✔: Possible, have
been shown by some studies; ✓: Theoretically possible and/or have only been shown by 1-2 studies

*MVO:* microvascular obstruction; *IMH:* intramyocardial hemorrhage; *EGE:* early gadolinium enhancement; *LGE:* late gadolinium enhancement; *ESA:* endocardial surface area

**Figure 2: The infarct core of a patient with microvascular obstruction and intramyocardial hemorrhage**

This figure shows an example of a patient with an acute anterior STEMI treated by PPCI and the CMR images on day 4 showing the infarct core on the late gadolinium enhancement images representing microvascular obstruction and on the T2*, T1 and T2 maps representing intramyocardial hemorrhage (arrows).

*LGE:* late gadolinium enhancement

**Figure 3: Delineation of the edema-based area-at-risk by T1 and T2-mapping, and MI size by late gadolinium enhancement that can be used to calculate myocardial salvage and myocardial salvage index**

The top panel shows an example of the edema-based area-at-risk by T1 and T2-mapping (indicated by black arrows) and the corresponding MI size on late gadolinium enhancement (red arrow) in a patient with an inferior STEMI treated by PPCI, with the CMR images acquired on day 3 post-reperfusion. The bottom panel shows the corresponding post-process images using a
threshold-based method to delineate the area-at-risk (threshold of 2 standard deviations) and MI size (threshold of 5 standard deviations) as the highlighted areas with the areas of hypointense core included as part of the area-at-risk and MI size. The myocardial salvage (area-at-risk subtract the MI size) and myocardial salvage index (myocardial salvage as a ratio of the area-at-risk) can be retrospectively calculated from a single CMR scan.

*LGE: late gadolinium enhancement*

**Figure 4 (a): Paired acute and follow-up T2* and T2 maps; (b): Paired acute and follow-up automated ECV maps of a patient with an inferior STEMI**

This figure shows an example of the paired acute and follow-up (6 months) late gadolinium enhancement and automated ECV maps, T2* and T2 maps of a patient with an inferior STEMI, treated by PPCI with restoration of normal flow in the infarct-related epicardial coronary artery. The arrows show the area of microvascular obstruction with intramyocardial hemorrhage. The corresponding ECV maps show the area of microvascular obstruction where contrast fails to penetrate the areas of microvascular obstruction and appears as pseudo-normal myocardium on the acute scan. At follow-up, the microvascular obstruction has resolved and the space previously occupied by the microvascular obstruction has very high ECV (white areas within the MI zone corresponding to the upper limit of the look-up color scale). The white regions of interest on the ECV maps (black arrows) are representative areas of the remote myocardium that can be used to assess changes in the
extracellular matrix. There was residual myocardial iron at follow-up and persistently elevated T2 in the areas surrounding the residual iron (blue arrows on the follow-up images.

*LGE: late gadolinium enhancement*
Table 1: Technical descriptions of the various components of the myocardium assessed by CMR in STEMI

<table>
<thead>
<tr>
<th>Components</th>
<th>Technical description</th>
</tr>
</thead>
</table>
| Native T1, post-contrast T1 and ECV | This is the time constant to recover 63% of its longitudinal magnetization (spin–lattice relaxation) and is expressed in milliseconds. It is referred to as native T1 when performed prior to the administration of gadolinium chelate. It is recommended that post-contrast T1 be performed at least 10 minutes following contrast administration. Once the native and post-contrast T1 of the blood and myocardium and the hematocrit are known, the ECV can be calculated using the formula below:

\[
ECV (\%) = (100–haematocrit) \times \frac{1/post-contrast T1_{myocardium}}{1/native T1_{myocardium}} - \frac{1/post-contrast T1_{blood}}{1/native T1_{blood}}
\]                                                                                                                                                                        |
| T2                                  | This refers to the constant representing the decay of transverse magnetization (spin-spin relaxation) to 37% of its initial equilibrium value and it is expressed in milliseconds.                                                                                                                                                                    |
| T2*                                 | This is the time constant representing the decay of transverse magnetization in the presence of local magnetic field inhomogeneities and is expressed in milliseconds.                                                                                                                                                                        |
| Parametric mapping                  | A process where an anatomical map is generated with each pixel representing a specific magnetic tissue property (T1, T2, or T2* or ECV) derived from the spatially corresponding voxel of a set of co-registered magnetic resonance source images.                                                                                                             |
| MI size                             | This refers to the mass or volume of infarcted myocardium, and is conventionally quantified by late gadolinium enhancement. After 10 minutes, pseudo-equilibrium of gadolinium chelate concentration between blood and well-perfused myocardium develops. During this time, a higher concentration of contrast is distributed in areas of acute or chronic MI (significantly shortening T1) than in normal myocardium. Therefore, with appropriate nulling of the remote myocardium using inversion recovery T1-weighted sequences, the necrotic or scarred areas appear bright. |
| Early microvascular obstruction     | This can be identified as areas of dark core within the MI zone using first-pass perfusion or EGE imaging performed with a fixed, high T1 (e.g. 440 to 500ms at 1.5T), acquired at 1-4 minutes post-contrast injection.                                                                                                           |
### Late microvascular obstruction
This can be identified as a dark core within the areas of hyperenhancement on conventional late gadolinium enhancement sequences acquired >10 minutes post-contrast injection.

### Intramyocardial hemorrhage
This can be identified using T2* -weighed imaging or T2*-mapping.

From brain imaging data, the degradation of the extravasated erythrocytes to oxyhemoglobin, deoxyhemoglobin, and methemoglobin (strongly paramagnetic) is dynamic and exhibits different magnetic properties at various stages as previously described by Bradley et al. Breakdown of the erythrocyte membrane eventually leads to ferritin and hemosiderin deposits within the macrophages and the iron-degradation products can be detected using T2* imaging.

Most studies have used a cut-off value for T2* of < 20 ms to detect intramyocardial hemorrhage but a threshold-based method of 2 standard deviations below the mean remote myocardial T2* can also be used. In centers where T2* imaging is not available, many studies have also used T2-weighted imaging but its diagnostic performance is less robust than T2*-weighted imaging.

### Area-at-risk
This refers to the territory supplied by the infarct-related artery and includes both the reversibility injured myocardial (the salvaged myocardium) and the infarcted myocardium. The area-at-risk can be indirectly assessed by CMR using late gadolinium enhancement imaging (to derive the endocardial surface area), T2-weighted imaging, T2-mapping, native T1-mapping, early gadolinium enhancement imaging, pre-contrast SSFP cine, and post-contrast SSFP cine imaging.

T1 and T2-mapping are currently considered the most robust of the CMR techniques as they have better contrast-to-noise ratio than the T2-weighted/ T1-weighted/ cine imaging techniques; they are less prone to blood pool and motion artifacts; and they are less likely to suffer from signal drop-out due to surface coil inhomogeneities.

### Myocardial Salvage and myocardial salvage index
Myocardial salvage can be calculated by subtracting the MI size from the area-at-risk.

The myocardial salvage index refers to the ratio of the myocardial salvage to the area-at-risk.

### Remote myocardium
This is usually defined as a myocardial segment 180° from the infarcted territory.

---

ECV: extracellular volume fraction; EGE: early gadolinium enhancement; CMR: cardiovascular magnetic resonance; SSFP: steady state free precession